Cidara Therapeutics Stock Alpha and Beta Analysis
| CDTX Stock | USD 221.38 0.06 0.03% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cidara Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cidara Therapeutics over a specified time horizon. Remember, high Cidara Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cidara Therapeutics' market risk premium analysis include:
Beta 0.4 | Alpha 1.74 | Risk 0.18 | Sharpe Ratio 0.25 | Expected Return 0.0453 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. Cidara Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cidara Therapeutics market risk premium is the additional return an investor will receive from holding Cidara Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cidara Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cidara Therapeutics' performance over market.| α | 1.74 | β | 0.40 |
Cidara Therapeutics Fundamentals Vs Peers
Comparing Cidara Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cidara Therapeutics' direct or indirect competition across all of the common fundamentals between Cidara Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cidara Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cidara Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cidara Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cidara Therapeutics to competition |
| Fundamentals | Cidara Therapeutics | Peer Average |
| Return On Equity | -0.69 | -0.31 |
| Return On Asset | -0.29 | -0.14 |
| Current Valuation | 6.54 B | 16.62 B |
| Shares Outstanding | 31.45 M | 571.82 M |
| Shares Owned By Insiders | 0.46 % | 10.09 % |
| Shares Owned By Institutions | 99.54 % | 39.21 % |
| Number Of Shares Shorted | 2.02 M | 4.71 M |
Cidara Therapeutics Opportunities
Cidara Therapeutics Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Merck Is Buying Cidara Therapeutics for 9.2 Billion. Is This the Boost the Lagging Drugmaker Needs | 11/20/2025 |
2 | Disposition of 10638 shares by Jeffrey Stein of Cidara Therapeutics subject to Rule 16b-3 | 12/19/2025 |
3 | Disposition of 5425 shares by Jeffrey Stein of Cidara Therapeutics subject to Rule 16b-3 | 12/22/2025 |
4 | Disposition of 450 shares by Davarpanah Nicole Negar of Cidara Therapeutics subject to Rule 16b-3 | 12/29/2025 |
5 | Acquisition by Ra Capital Management, L.p. of 1286786 shares of Cidara Therapeutics at 1.0E-4 subject to Rule 16b-3 | 01/06/2026 |
About Cidara Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cidara or other stocks. Alpha measures the amount that position in Cidara Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Interest Debt Per Share | 1.12 | 0.56 | 0.65 | 0.62 | Revenue Per Share | 5.33 | 0.2 | 0.23 | 0.22 |
Cidara Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Cidara Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cidara Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cidara Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cidara Therapeutics. Please utilize our Beneish M Score to check the likelihood of Cidara Therapeutics' management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cidara Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.